The rising prevalence of venous thromboembolism-related disorders is predicted to drive the apixaban market forward. According to the International Society on Thrombosis and Haemostasis 2014 statistics, around 10 million cases of venous thromboembolism occur each year throughout poor, middle, and high income nations. Furthermore, expanding therapeutic indications for apixaban are likely to drive apixaban market expansion. For example, the United States Food and Drug Administration authorised Eliquis in 2014 for the prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for lowering the risk of recurrent PE and DVT after initial therapy.
Read More:
https://knackersblogger.blogspot.com/2022/10/apixaban-market-size-share-outlook-and.html
